ReviewVaccines2023
Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential of circulating microRNAs as novel diagnostic biomarkers of COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Article
- Improving CNN predictive accuracy in COVID-19 health analytics.Scientific reports · 2025Article
- Evaluation of a surrogate virus neutralization assay for detecting neutralizing antibodies against SARS-CoV-2 in an African population.Biology methods & protocols · 2025Article
- SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.Vaccines · 2024Review
- Mass Spectrometry-Based Metabolomics Reveals a Salivary Signature for Low-Severity COVID-19.International journal of molecular sciences · 2024Article
- Unveiling the promise: Exosomes as game-changers in anti-infective therapy.Exploration (Beijing, China) · 2024Review
- Comparative Analysis of QCM and Electrochemical Aptasensors for SARS-CoV-2 Detection.Biosensors · 2024Article
- Article
- A Novel COVID-19 Diagnosis Approach Utilizing a Comprehensive Set of Diagnostic Information (CSDI).Journal of clinical medicine · 2023Article
- Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design.Pharmaceutics · 2023Review
- Seminal fluid changes in the COVID-19 era: During infection and Post-vaccination.Gynecology and obstetrics clinical medicine · 2023Review
- A review of current effective COVID-19 testing methods and quality control.Archives of microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate identification at an early stage of infection is critical for effective care of any infectious disease. The "coronavirus disease 2019 (COVID-19)" outbreak, caused by the virus "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", corresponds to the current and global pandemic, characterized by several developing variants, many of which are classified as variants of concern (VOCs) by the "World Health Organization (WHO, Geneva, Switzerland)". The primary diagnosis of infection is made using either the molecular technique of RT-PCR, which detects parts of the viral genome's RNA, or immunodiagnostic procedures, which identify viral proteins or antibodies generated by the host. As the demand for the RT-PCR test grew fast, several inexperienced producers joined the market with innovative kits, and an increasing number of laboratories joined the diagnostic field, rendering the test results increasingly prone to mistakes. It is difficult to determine how the outcomes of one unnoticed result could influence decisions about patient quarantine and social isolation, particularly when the patients themselves are health care providers. The development of point-of-care testing helps in the rapid in-field diagnosis of the disease, and such testing can also be used as a bedside monitor for mapping the progression of the disease in critical patients. In this review, we have provided the readers with available molecular diagnostic techniques and their pitfalls in detecting emerging VOCs of SARS-CoV-2, and lastly, we have discussed AI-ML- and nanotechnology-based smart diagnostic techniques for SARS-CoV-2 detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.